Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Metabolic Engineering|December 21, 2016
Step changes in leaf oil accumulation via iterative metabolic engineeringThomas Vanhercke, Uday K Divi, Anna El Tahchy, et al.
Acta Pharmacologica Sinica|October 16, 2024
Mettl1 knockdown alleviates cardiac I/R injury in mice by inactivating the Mettl1-CYLD-P53 positive feedback loopShu-Ting Yu, Zhi-Yong Sun, Na Li, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer|July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective StudyLin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Communications Medicine|March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)Da-Long Yang, Chuang Qin, Ning Peng, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)Da-Long Yang, Yi-He Yan, Yong-Cheng Lai, et al.
Pageof 5